Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

Fig. 3

Addition of 4-1BB agonist improves yield of CD8+ pancreatic TIL. a Pancreatic tumor digests were assessed for 4-1BB expression by flow cytometry. The data represent mean + SD (n = 3). Separately, fragments of pancreatic tumors were initially plated in TIL CM containing 6000 I.U./mL IL-2 and 10 ug/mL anti-4-1BB antibody or IgG4 isotype control. TIL were subsequently cultured according to standard techniques, with the addition of 1 ug/mL anti-4-1BB or isotype. b Viable TIL were counted by trypan blue exclusion after pre-REP expansion and reported as a fold change over isotype control for each patient total (n = 3 patients). Significance was determined by the Wilcoxon signed rank test. c Pancreatic TIL were then analyzed by flow cytometry for CD3, CD4, CD8 expression on live lymphocytes. Absolute numbers were derived from cell counts and percentages based on FACS analysis on a per fragment basis. Statistical significance was determined by the Mann-Whitney Test (n = 3 patients). Data are reported as mean % ± SD

Back to article page